Subtle Medical receives $1.6M grant to limit gadolinium use with AI

Subtle Medical has received a grant for up to $1.6 million from the National Institutes of Health (NIH) to develop an AI solution, SubtleGAD, that could reduce the amount of gadolinium used during MRI scans. The Small Business Innovation Research grant is contingent on certain deliverables.

“With SubtleGAD technology, hospitals and imaging centers will be able to deliver safer MRI exams without sacrificing the clinical quality of the images,” Enhao Gong, PhD, co-founder and CEO of Subtle Medical, said in a prepared statement. “We are grateful to receive NIH's support to further the development of our AI product and bring it into clinical use.”

SubtleGAD is Subtle Medical’s third AI solution. The other two are the FDA-approved SubtlePET and SubtleMR, which is currently under FDA review.

Gadolinium retention after the use of gadolinium-based contrast agents (GBCA) has been a big topic in healthcare in recent years. For more coverage of the use of GBCAs in medical imaging, click here and here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.